Gyre Therapeutics Inc (GYRE)
NASDAQ
News
Market Data
Register to chat with like-minded investors on our interactive forums.
Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop val... Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in the clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants. Show more
Ask ADVFN Intelligence (AI)
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.0182 | 10.2519180813 | 9.9318 | 11.11 | 9.51 | 106538 | 10.36716261 | CS |
| 4 | 0.35 | 3.30188679245 | 10.6 | 14.4228 | 9.51 | 127676 | 10.98907779 | CS |
| 12 | -3.41 | -23.7465181058 | 14.36 | 19 | 9.51 | 107586 | 11.62054536 | CS |
| 26 | -4.56 | -29.4003868472 | 15.51 | 19 | 8.26 | 75493 | 12.13454044 | CS |
| 52 | -12.18 | -52.6588845655 | 23.13 | 26.37 | 8.26 | 76308 | 13.57828875 | CS |
| 156 | 3.95 | 56.4285714286 | 7 | 30.4 | 5.88 | 83344 | 15.25436592 | CS |
| 260 | 3.95 | 56.4285714286 | 7 | 30.4 | 5.88 | 83344 | 15.25436592 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
